Reuters exclusively reports Eli Lilly memo says firm did not make false statements to FDA

Reuters reported exclusively that a week before Eli Lilly disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there. The law firm was tapped to investigate alleged alterations of documents, which employees said were meant to downplay serious quality control problems at the plant producing the company’s COVID-19 antibody treatment. 

Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: Americas
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story
Sign up for email updates

Sign up for email updates